In Vivo Pre-clinical characterization of a Novel Series of FGFR2 Selective Inhibitors with Potency Against Clinically Relevant Mutations

被引：0

作者：

Fischer, J. ^{[1
]}

Bouhana, K. ^{[1
]}

Chicarelli, M. J. ^{[1
]}

Dahlke, J. ^{[1
]}

Fell, B. ^{[1
]}

Fulton, J. ^{[1
]}

Guarnieri, A. ^{[1
]}

Haygood, L. ^{[1
]}

Jalluri, R. ^{[1
]}

Johnson, A. ^{[1
]}

McLean, B. ^{[1
]}

Max, M. ^{[1
]}

Rieger, R. ^{[1
]}

Robinson, J. ^{[1
]}

Rodriguez, M. ^{[1
]}

Sullivan, F. ^{[1
]}

Wang, Y. ^{[1
]}

Winski, S. ^{[1
]}

Zhou, Y. ^{[1
]}

机构：

[1] Cogent Biosci, Res Dev, Boulder, CO USA

来源：

EUROPEAN JOURNAL OF CANCER | 2022年 / 174卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

227

引用

页码：S81 / S81

页数：1

共 46 条

[41] PF-06463922, a novel next generation ALK/ROS1 inhibitor, overcomes resistance to 1st and 2nd generation ALK inhibitors in pre-clinical models
Friboulet, Luc
Zou, Helen
Kodack, David P.
Engstrom, Lars D.
Li, Qiuhua
West, Melissa
Tang, Ruth W.
Wang, Hui
Tsaparikos, Konstantinos
Wang, Jinwei
Timofeevski, Sergei
Dinh, Dac M.
Hieu Lam
Lam, Justine L.
Yamazaki, Shinji
Hu, Wenyue
Patel, Bhushankumar
Bezwada, Divya
Mahmood, Sidra
Lifshits, Eugene
Affolter, Timothy
Lappin, Patrick B.
Gukasyan, Hovhannes
Lee, Nathan
Deng, Shibing
Jain, Rakesh K.
Johnson, Ted W.
Shaw, Alice T.
Fantin, Valeria R.
Smeal, Tod
CANCER RESEARCH, 2015, 75
[42] Excellent efficacy and pharmacokinetics have been demonstrated in pre-clinical and Phase I/II studies by AIC316, a novel drug against herpes simplex virus (HSV) type 1 and 2
Birkmann, A.
McCormick, D.
Kropeit, D.
Timmler, B.
Stoelben, S.
Wald, A.
Richard, M. P.
Zimmermann, H.
Ruebsamen-Schaeff, H.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2012, 10 : 29 - 29
[43] Synergistic Pre-Clinical Activity of Combined Epigenetic Therapy with the Novel Histone Methyltransferase EZH2 Inhibitor 3-Deazaneplanocin and Histone Deacetylase Inhibitor Panobinostat against Human AML Cells
Fiskus, Warren
Wang, Yongchao
Jillella, Anand
Ustun, Celalettin
Johnston, Pace
Joshi, Rajeshree
Rao, Rekha
Ataja, Peter
Marquez, Victor
Bhalla, Kapil N.
BLOOD, 2008, 112 (11) : 1152 - 1152
[44] Synthesis, structure -: Activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors.: 1.: Thiazolone and oxazolone series
Song, YT
Connor, DT
Doubleday, R
Sorenson, RJ
Sercel, AD
Unangst, PC
Roth, BD
Gilbertsen, RB
Chan, K
Schrier, DJ
Guglietta, A
Bornemeier, DA
Dyer, RD
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (07) : 1151 - 1160
[45] Pre-clinical development as microbicide of zinc tetra-ascorbo-camphorate, a novel terpenoid derivative: Potent in vitro inhibitory activity against both R5- and X4-tropic HIV-1 strains without significant in vivo mucosal toxicity
Saïdi H.
Jenabian M.-A.
Gombert B.
Charpentier C.
Mannarini A.
Bélec L.
AIDS Research and Therapy, 5 (1)
[46] Synthesis, structure -: Activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors.: 2.: 1,3,4- and 1,2,4-thiadiazole series
Song, YT
Connor, DT
Sercel, AD
Sorenson, RJ
Doubleday, R
Unangst, PC
Roth, BD
Beylin, VG
Gilbertsen, RB
Chan, K
Schrier, DJ
Guglietta, A
Bornemeier, DA
Dyer, RD
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (07) : 1161 - 1169

← 1 2 3 4 5 →